Table 4.
Correlation analysis of SCC antigen levels with overall survival of patients with cervical squamous cell carcinoma
| Variable | Mean survival times (months) | χ2 | P |
|---|---|---|---|
| SCC antigen levels before chemotherapy | 0.095 | 0.758 | |
| NACT group (n = 63) | 40.16 (37.24, 43.07) | ||
| Conventional group (n = 39) | 33.43 (31.31, 35.56) | ||
| NACT group | 0.098 | 0.754 | |
| Chemotherapy-insensitive group (n = 32) | 41.19 (37.29, 45.08) | ||
| Chemotherapy-sensitive group (n = 31) | 39.25 (35.01, 43.50) | ||
| SCC antigen levels in NACT group before chemotherapy | 9.880 | 0.002 | |
| < 4.55 (n = 29) | NA a | ||
| ≥ 4.55 (n = 34) | NA a | ||
| SCC antigen levels ≥4.55 before chemotherapy | 4.176 | 0.041 | |
| NACT group (n = 34) | 36.40 (31.59, 41.22) | ||
| Conventional group (n = 21) | 32.95 (30.95, 34.96) | ||
| SCC antigen levels in NACT group after the first chemotherapy | 10.869 | 0.001 | |
| < 2.70 (n = 39) | 43.75 (42.07, 45.43) | ||
| ≥ 2.70 (n = 24) | 34.40 (28.99, 40.81) |
a, in NACT group before chemotherapy, when SCC antigen levels < 4.55 ng/mL, 29 patients were survival and it is impossible to calculate the survival times of patients